The increased insulin density in the pancreatic cancer microenvironment and IR overexpression in cancer cells finally lead to the failure of IGF-1R inhibitor in pancreatic cancer trials (Buck et al., 2010; Ulanet et al., 2010; Garofalo et al., 2011). This evidence concerns the gene INS and pancreatic neoplasm.